The significant expression of PD-1/PDL1/PD-L2 molecules by both human and canine melanomas suggests exploitation of inhibitory strategies could potentiate the effects of TIL (tumor infiltrating lymphocyte) therapy on canine melanomas [53]. Here, PDCD1LG2 is linked to melanoma.